Abbott Laboratories (ABT)

US — Healthcare Sector
Peers: NVO  MRK  TMO  NVS  BSX  MDT  SYK  ISRG  UNH  GILD 

Automate Your Wheel Strategy on ABT

With Tiblio's Option Bot, you can configure your own wheel strategy including ABT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

2 Healthcare Names That Could Get a Big Boost From Earnings
ABT, ISRG
Published: January 20, 2026 by: MarketBeat
Sentiment: Positive

Active traders expect companies in the healthcare sector to experience significant share price spikes tied to milestones in the development of new therapies and medical products. The volatility in some corners of the sector makes it a high-risk, but high-reward, opportunity.

Read More
image for news 2 Healthcare Names That Could Get a Big Boost From Earnings
Will Robust Adult Nutrition Business Performance Fuel ABT's Q4 Earnings?
ABT
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Positive

ABT heads into Q4 earnings with adult nutrition in focus, as Ensure and Glucerna launches are expected to support modest segment growth.

Read More
image for news Will Robust Adult Nutrition Business Performance Fuel ABT's Q4 Earnings?
Exact Sciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS
ABT, EXAS
Published: January 16, 2026 by: PRNewsWire
Sentiment: Neutral

NEW YORK and NEW ORLEANS, Jan. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Read More
image for news Exact Sciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS
Insights Into Abbott (ABT) Q4: Wall Street Projections for Key Metrics
ABT
Published: January 16, 2026 by: Zacks Investment Research
Sentiment: Positive

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Abbott (ABT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.

Read More
image for news Insights Into Abbott (ABT) Q4: Wall Street Projections for Key Metrics
Dividend King Abbott Shows Why 52 Consecutive Increases Weren't Luck With Strong Cash Flow Coverage
ABT
Published: January 15, 2026 by: 24/7 Wall Street
Sentiment: Positive

Abbott Laboratories (NYSE: ABT) doesn't just pay dividends.

Read More
image for news Dividend King Abbott Shows Why 52 Consecutive Increases Weren't Luck With Strong Cash Flow Coverage
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
ABT
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
PBH or ABT: Which Is the Better Value Stock Right Now?
ABT, PBH
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive

Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two stocks is more attractive to value investors?

Read More
image for news PBH or ABT: Which Is the Better Value Stock Right Now?
Abbott: Not Cheap, But Built To Compound In Uncertain Markets
ABT
Published: January 07, 2026 by: Seeking Alpha
Sentiment: Neutral

Abbott Laboratories is a defensive, high-quality compounder with a premium valuation justified by recurring cash flow and strong medical device platforms. Medical Devices, especially Diabetes Care (Libre), are driving over 12% segment growth, with Diabetes Care revenues surpassing $2B and growing 17%. ABT reaffirmed 2025 organic growth guidance of 7.5%–8% and EPS of $5.12–$5.18, with consistent, low-volatility earnings growth expected through 2027.

Read More
image for news Abbott: Not Cheap, But Built To Compound In Uncertain Markets
PBH vs. ABT: Which Stock Is the Better Value Option?
ABT, PBH
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Neutral

Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?

Read More
image for news PBH vs. ABT: Which Stock Is the Better Value Option?
Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions
ABT
Published: January 05, 2026 by: PRNewsWire
Sentiment: Neutral

Traditional food logging apps offer feedback after the fact—Libre Assist1 offers help in-the-moment to inform mealtime decisions before every bite Libre Assist1 leverages AI to predict how food choices affect glucose levels,2 provides personalized meal guidance,3 and confirms glucose impact using data from Abbott's world-leading FreeStyle Libre continuous glucose monitoring (CGM) technology4 Abbott is launching Libre Assist, available at no additional cost within the Libre app,5 during CES® 2026 ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a leading healthcare company, today unveiled Libre Assist,1 a groundbreaking feature within the Libre app5 designed to help the millions …

Read More
image for news Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
ABT
Published: December 31, 2025 by: Zacks Investment Research
Sentiment: Positive

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More
image for news Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
Best Dividend Aristocrats For January 2026
ABBV, ABT, ADM, ADP, AFL, ALB, AMCR, AOS, APD, ATO, BDX, BEN, BRO, CAH, CAT, CB, CHD, CHRW, CINF, CL, CLX, CTAS, CVX, DOV, ECL, BF-A, BF-B, ED, EMR, ERIE, ES, ESS, EXPD, FAST, FDS, FRT, GD, GPC, GWW, HRL, IBM, ITW, JNJ, KMB, KO, KVUE, LIN, LOW, MCD, MDT, MKC, NDSN, NEE, NOBL, NUE, O, PEP, PG, PNR, PPG, ROP, SHW, SJM, SPGI, SPY, SWK, SYY, TGT, TROW, WMT, WST, XOM
Published: December 31, 2025 by: Seeking Alpha
Sentiment: Positive

The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.

Read More
image for news Best Dividend Aristocrats For January 2026
Abbott Stock May Benefit Following Volt PFA's FDA Approval
ABT
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive

ABT wins FDA approval for its Volt PFA System for AFib, paving the way for U.S. launches and EU expansion after earlier CE Mark clearance.

Read More
image for news Abbott Stock May Benefit Following Volt PFA's FDA Approval
Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation
ABT
Published: December 22, 2025 by: PRNewsWire
Sentiment: Neutral

Abbott's Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation – or PFA – is a minimally invasive procedure that uses high-energy electrical pulses in targeted areas of the heart to treat irregular heart rhythms Abbott's Volt PFA System is an all-in-one product that is clinically proven to simplify the treatment of AFib that is gentler on the heart, has shorter procedure times and supports better recovery and long-term results ABBOTT PARK, Ill., Dec. 22, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced …

Read More
image for news Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation
Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart
ABT
Published: December 18, 2025 by: PRNewsWire
Sentiment: Neutral

First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise placement of Abbott's Amplatzer Piccolo Occluder in the tiniest babies A PDA requiring treatment is present in approximately 20% of premature infants1 ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer Piccolo™ Delivery System, which is used with the company's Amplatzer Piccolo Occluder.

Read More
image for news Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart
PBH vs. ABT: Which Stock Should Value Investors Buy Now?
ABT, PBH
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?

Read More
image for news PBH vs. ABT: Which Stock Should Value Investors Buy Now?
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
ABT
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More
image for news Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
Abbott Gains From Lingo CGM's Expansion on Android Platform
ABT
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive

ABT expands its Lingo biowearable to Android, broadening access to real-time glucose tracking and pushing continuous monitoring into mainstream wellness.

Read More
image for news Abbott Gains From Lingo CGM's Expansion on Android Platform
Abbott increases quarterly dividend for 54th consecutive year
ABT
Published: December 12, 2025 by: PRNewsWire
Sentiment: Neutral

Quarterly dividend increased by 6.8% Quarterly dividend payout has increased more than 70% since 2020 408th consecutive quarterly dividend to be paid by Abbott since 1924 ABBOTT PARK, Ill., Dec. 12, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 63 cents per share, an increase of 6.8%.

Read More
image for news Abbott increases quarterly dividend for 54th consecutive year
Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement
ABT
Published: December 04, 2025 by: PRNewsWire
Sentiment: Neutral

Aging, nutrition and lifestyle affect muscles, especially after age 40. That's why Matt Ryan, former professional quarterback and MVP, is teaming up with Abbott to drive muscle health awareness with two new Ensure Max Protein shakes Ensure Max Protein 42g: For physically active adults, this new shake delivers 42 grams of complete protein to help build muscle tissue alongside resistance training with 23 vitamins and minerals and two key electrolytes to support muscle function Ensure Max Protein 2 in 1 Muscle Support: For older adults who need help maintaining muscle as they age, this shake has 30 grams of protein …

Read More
image for news Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
ABT
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Read More
image for news Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
PBH or ABT: Which Is the Better Value Stock Right Now?
ABT, PBH
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two stocks is more attractive to value investors?

Read More
image for news PBH or ABT: Which Is the Better Value Stock Right Now?
Abbott to buy Exact Sciences for $21B in cancer diagnostics reach push
ABT, EXAS
Published: November 20, 2025 by: Proactive Investors
Sentiment: Positive

Abbott Laboratories (NYSE:ABT) on Thursday announced a definitive agreement to acquire cancer diagnostics company Exact Sciences (NASDAQ:EXAS) in a deal valued at approximately $21 billion. Exact Sciences, known for its noninvasive colorectal cancer screening test Cologuard and multi-cancer early detection test Cancerguard, reported projected revenue of more than $3 billion this year, with high-teens organic growth.

Read More
image for news Abbott to buy Exact Sciences for $21B in cancer diagnostics reach push
Abbott is weighing takeover of Exact Sciences, Bloomberg News reports
ABT, EXAS
Published: November 19, 2025 by: Reuters
Sentiment: Positive

Medical device maker Abbott Laboratories is nearing a potential takeover of cancer test maker Exact Sciences Corp , Bloomberg News reported on Wednesday, citing people familiar with the matter.

Read More
image for news Abbott is weighing takeover of Exact Sciences, Bloomberg News reports
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
ABT
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Read More
image for news Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Why Is Abbott (ABT) Up 1.3% Since Last Earnings Report?
ABT
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive

Abbott (ABT) reported earnings 30 days ago. What's next for the stock?

Read More
image for news Why Is Abbott (ABT) Up 1.3% Since Last Earnings Report?
Goldman Sachs Says US Stocks Could Lag for 10 Years: 5 Strong Buy Value Dividend Ideas
ABT, HSY, MO, T, VLO
Published: November 13, 2025 by: 24/7 Wall Street
Sentiment: Neutral

Goldman Sachs has projected that U.S. stocks will deliver lackluster returns over the next decade primarily due to two key factors: extreme market concentration and elevated valuations.

Read More
image for news Goldman Sachs Says US Stocks Could Lag for 10 Years: 5 Strong Buy Value Dividend Ideas
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
ABT
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More
image for news Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Abbott Showcases World's First Dual Chamber Leadless Pacemaker in National Media Tour Featuring Patient Story with YourUpdateTV
ABT
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

Boston Teacher Shares Life-Changing Experience with Breakthrough Dual Chamber Leadless Pacemaker During Nationwide Interviews in Conjunction with D S Simon Media Boston Teacher Shares Life-Changing Experience with Breakthrough Dual Chamber Leadless Pacemaker During Nationwide Interviews in Conjunction with D S Simon Media

Read More
image for news Abbott Showcases World's First Dual Chamber Leadless Pacemaker in National Media Tour Featuring Patient Story with YourUpdateTV
HOLX vs. ABT: Which Medical Technology Stock Is the Better Investment?
ABT, HOLX
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive

Hologic's $18.3B buyout deal and Abbott's strong growth across key segments set up a close contest for MedTech investors.

Read More
image for news HOLX vs. ABT: Which Medical Technology Stock Is the Better Investment?

About Abbott Laboratories (ABT)

  • IPO Date 1980-03-17
  • Website https://www.abbott.com
  • Industry Medical - Devices
  • CEO Robert Ford
  • Employees 114000

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.